ABBV

AbbVie Inc.

ABBV · CIK 1551152

Latest 10-K filed February 20, 2026 · period ending December 31, 2023

Headline figures

Revenue

$54.32B

-6.4% vs prior year

Top-line sales for the most-recent fiscal year

FY2025 · 10-K

Net income

$4.86B

-58.9% vs prior year

Profit after all expenses, taxes, interest

FY2025 · 10-K

EPS (diluted)

$2.72

-59.0% vs prior year

Net income per diluted share outstanding

FY2025 · 10-K

Op. cashflow

$22.84B

-8.4% vs prior year

Cash actually generated by the business

FY2025 · 10-K

Balance sheet

Total assets

$135.16B

Everything the company owns

FY2025 · 10-K

Total liabilities

—

Everything the company owes

Stockholders equity

$3.33B

Assets minus liabilities (book value)

FY2025 · 10-K

Long-term debt

$64.50B

Debt due more than 12 months out

FY2025 · 10-K

Revenue history

Revenues · FY values from Revenues

Fiscal year	Revenue	vs prior	Source
FY2025	$54.32B	-6.4%	10-K
FY2024	$58.05B	+3.3%	10-K
FY2023	$56.20B	+22.7%	10-K
FY2022	$45.80B	+37.7%	10-K
FY2021	$33.27B	—	10-K

Read the source

All figures on this page were filed by AbbVie Inc. with the SEC and pulled directly from EDGAR's XBRL CompanyFacts API. Click below to view the latest annual report (10-K) in full.

Open latest 10-K on SEC EDGAR →

Not investment advice. Figures sourced from the SEC's XBRL CompanyFacts API — public-domain federal records. Companies occasionally restate prior-year numbers; we show the latest filed value per fiscal year.